Mediclinic International sees return to growth in fiscal 2022 despite further Covid-19 waves ahead

Writer,

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Health care company Mediclinic International said it expected improved performance in fiscal 2022 despite a further waves of Covid-19 expected in the coming weeks.

'We are well positioned to deliver growth in revenue and EBITDA across all three divisions in FY22 despite further waves of the pandemic expected in the coming months, especially in Switzerland and Southern Africa,' the company said.

The upbeat outlook comes as annual revenue fell 3% year-on-year in fiscal 2021, as weaker first-half performance offset an improved second-half.

Stronger demand in 2H21 delivered revenue growth of around 1%, and drove improvement in margins.

Results for the financial year ended 31 March 2021 is scheduled for 26 May 202

At 9:06am: (LON:MDC) Mediclinic International PLC share price was 0p at 316p